Nyxoah's Upcoming Earnings Announcement
Nyxoah, a pioneering force in the realm of obstructive sleep apnea (OSA) treatment, is gearing up to share its financial performance for the last quarter and the entire fiscal year of 2024. On March 13, 2025, the company will reveal critical insights about its financial results. This provides an excellent opportunity for investors and stakeholders to gain a comprehensive understanding of Nyxoah's progress and future directions.
Conference Call Details
To discuss these results, the company will host a conference call at 1:00 PM CET / 8:00 AM ET. This call will allow management to delve deeper into the numbers and share the company’s strategic vision. While a live webcast will be available on Nyxoah's Investor Relations page, anyone wishing to ask questions during the call is encouraged to register early. This ensures a seamless experience as late registrations may complicate access.
How to Join the Webcast
The investor community is encouraged to tune into the earnings call webcast. Nyxoah has made it easy for listeners, with a user-friendly interface accessible directly through their website. This caters both to those wishing to listen intently and those ready to engage directly with the team by posing questions.
Recordings for Future Reference
For those unable to join the live call, Nyxoah intends to archive the webcast, which will be available for replay shortly after the session ends. This is an excellent way for interested parties to catch up on the insights shared during the discussion.
About Nyxoah
Nyxoah is leading the charge in transforming how patients with obstructive sleep apnea manage their condition. Their flagship product, Genio®, epitomizes innovation. This battery-free device is designed to be implanted through a minor incision, showcasing Nyxoah's commitment to minimally invasive therapeutic options. It is controlled by a convenient wearable, allowing for ease of use while addressing a significant health issue that affects millions globally.
Clinical Impact and Achievements
Since its CE Mark approval in 2019, Nyxoah has made remarkable strides. The successful BLAST OSA study has only added to the credibility of its offerings. Additionally, recent clinical trials have expanded the therapeutic indications of the Genio® system to include patients with Complete Concentric Collapse (CCC). This approval showcases the company's robust growth and reveals its competitive edge in the evolving OSA treatment landscape.
Investing in Healthier Sleep
As more individuals become aware of the consequences of untreated OSA, Nyxoah’s innovative solutions have placed the company in a prime position to lead the market. Their focus on ongoing clinical studies and research further highlights their dedication to improving patient outcomes. With each step forward, Nyxoah demonstrates its potential to change lives and provide lasting relief for those affected by sleep disorders.
Frequently Asked Questions
What financial results will Nyxoah release?
Nyxoah will share its financial results for the fourth quarter and the entire financial year 2024.
When will the earnings call occur?
The earnings call is scheduled for March 13, 2025, at 1:00 PM CET / 8:00 AM ET.
How can I participate in the earnings call?
Participants can listen via the webcast or register to ask questions during the call by following the instructions provided on Nyxoah's Investor Relations page.
Is the webcast accessible after the call?
Yes, the archived webcast will be available shortly after the call for anyone wishing to listen at their convenience.
What is the significance of Genio®?
Genio® is Nyxoah's innovative solution for obstructive sleep apnea, providing patients with an alternative treatment method through a minimally invasive procedure.
